OPYL LIMITED(OPL)

name changed to Pathkey.AI Ltd

The suspension of trading in the securities of Opyl Limited will be lifted immediately following the release by OPL of an announcement regarding a non-binding offer to acquire the Opin business from OPL.

The Company has received a non-binding offer to acquire its patient candidate recruitment business, Opin, from Trial Screen Pty Ltd, an entity controlled by Dr Hugo Stephenson. The non-binding offer proposes a divestment of Opin for A$1 and 20% of the equity in Trial Screen. The divestment is expected to be completed by 30 April 2024. The divestment of Opin will be subject to shareholder approval under ASX Listing Rule 11.2. As part of the sale, Opyl will transfer all Opin related intellectual property, key employees, key clients, and brand assets pertaining to the Opin business. The divestment will significantly improve Opyl's monthly cashflow and enable greater focus on driving growth for TrialKey, noting Opin was responsible for approximately $700K ($60k per month) in net cash outflows per year on a standalone basis. The divestment will enable the Company to redeploy capital and resources towards its AI solution TrialKey advancing its ongoing commercialisation.

The Company has received a non-binding offer to acquire its patient candidate recruitment business, Opin, from Trial Screen Pty Ltd, an entity controlled by Dr Hugo Stephenson. The non-binding offer proposes a divestment of Opin for A$1 and 20% of the equity in Trial Screen. The divestment is expected to be completed by 30 April 2024. The divestment of Opin will be subject to shareholder approval under ASX Listing Rule 11.2. As part of the sale, Opyl will transfer all Opin related intellectual property, key employees, key clients, and brand assets pertaining to the Opin business. The divestment will significantly improve Opyl's monthly cashflow and enable greater focus on driving growth for TrialKey, noting Opin was responsible for approximately $700K ($60k per month) in net cash outflows per year on a standalone basis. The divestment will enable the Company to redeploy capital and resources towards its AI solution TrialKey advancing its ongoing commercialisation.

The securities of Opyl Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of OPL, pending the release of an announcement regarding a non-binding offer to acquire the Opin business from OPL.

The suspension of trading in the securities of Opyl Limited will be lifted immediately following the release of an announcement by OPL regarding an entitlement offer.

The company releases a Cleansing Notice regarding the entitlement offer.

The company releases a notice of proposed issue of securities.

Opyl has successfully completed a $576,000 placement at an offer price of $0.03 per share from professional and sophisticated investors. A 2 for 5 non-renounceable rights issue offer at $0.03 per share is also being offered to eligible shareholders to raise up to $1.43m. Opyl has secured advanced commitments for $635,000 in a combination of rights acceptances in advance and shortfall commitments prior to the Entitlement Offering opening date. Proceeds from both the placement and rights issue will be used to progress the commercialisation of Opyl's recently launched predictive analytics and clinical trial insights platform, TrialKey.

The securities of Opyl Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of OPL, pending the release of an announcement regarding an entitlement offer.

The suspension of trading in the securities of Opyl Limited will be lifted immediately following the release by OPL of an announcement regarding a capital raise.

The company releases a Rights Issue Offer Booklet.

The company announces a non-renounceable rights issue, to raise up to $480,390. The funds raised from the placement and rights issue will be applied to: accelerating the conversion of the sales pipeline, development and release of additional functionality on Opin that provides for greater automation connecting patients to trial sites, supporting scale and additional income stream, expansion of Opin into key APAC markets (NZ, Korea and Taiwan) and first entry into US markets, ongoing product development and enhancement, working capital.

The company releases a letter to its ineligible shareholders regarding the rights issue.

The company releases a cleansing notice in relation to its nonrenounceable rights issue offer to eligible shareholders.

The company makes a clarification on its announcement. The company wants to correct this statement: "The Placement Shares are intended to be issued under the Company's current capacity pursuant to ASX Listing Rule 7.1(8,157,808 Shares) and 7.1A (5,438,538 Shares)." This should state: The Placement Shares are intended to be issued under the Company's current, capacity pursuant to ASX Listing Rule 7.1(8,157,808 Shares) and 7.1A (1,508,859 Shares).

The company releases a notice of proposed issue of securities.

Opyl has successfully received commitments from institutional and sophisticated investors for approximately $290,000 at $0.03 via a placement. A 1 for 4 non-renounceable rights issue offer at $0.03 per share is being offered to eligible shareholders to raise up to A$480,390. A top-up facility will be offered, under which eligible shareholders can apply to take up new shares in excess of their pro-rata entitlement. Proceeds from the raises will be used to extend Opin's market share in APAC, accelerate conversion of the sales pipeline, open new functionality in Opin, ongoing product development and enhancement and improve working capital.

The securities of Opyl Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of OPL, pending the release of an announcement regarding a capital raise

The suspension of trading in the securities of Opyl Limited will be lifted immediately following the release by OPL of an announcement regarding the Company's announcement dated 3 September 2020.

The company provides additional information in relation to its announcement on 3 September 2020. The cost of the product to date has been circa $800k. The software is now functional however the company will continue to further improve and refine the software with future upgrades and expansion of features, which is anticipated to cost up to another $500K in development. The company will continue to develop its marketing, sales and ongoing customer service support expenditure forecast models as well as revenue models and provides shareholders and the market with updates. The company is currently finalising its R&D application for the 2020 financial year.

The securities of Opyl Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of OPL, pending the release of an announcement.

In reference to the two new contracts, individually, these do not represent a material event as they will not increase the company's forecast revenue by greater than 10% for the year ended 30 June 2020. The intention of the company's announcement on 20 May 2020 is to provide shareholders regular and ongoing overview in respect of its progress. Additional information in relation to these contracts have been provided.

The suspension of trading in the securities of Opyl Limited ("˜OPL') will be lifted from the commencement of trading on Tuesday, 26 May 2020, following the release by OPL of an announcement regarding the two new contracts announced on Wednesday 20 May 2020.

The securities of Opyl Limited will be suspended from quotation from the commencement of trading on Friday 22 May 2020 under Listing Rule 17.2, at the request of OPL, pending the release of an announcement regarding the two new contracts announced on Wednesday 20 May 2020.

name changed from ShareRoot Ltd